MEDIUM confidence: 100% data completeness, but the composite (58) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Net insider -$2.0M over 180 days (0 open-market buys, 4 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $664M— | $767M+15.6% | $929M+21.1% | $1.0B+12.2% | $1.1B+3.7% |
| EPS (dil.) | $1.72— | $2.03+18.0% | $2.82+38.9% | $3.51+24.5% | $3.60+2.6% |
| Free Cash Flow | $181M— | $173M-4.5% | $241M+39.6% | $286M+18.6% | $374M+30.6% |
| Gross Margin | 53.9% | 52.4%-1.5pp | 53.0%+0.6pp | 54.2%+1.2pp | 55.7%+1.5pp |
| Operating Margin | 20.2% | 19.9%-0.3pp | 22.6%+2.7pp | 25.1%+2.5pp | 26.1%+1.0pp |
| Net Margin | 16.6% | 16.8%+0.2pp | 19.0%+2.2pp | 20.9%+1.9pp | 20.3%-0.6pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $265 (last qtr, 5 analysts) → $285 (last mo, 3) (+7.5%).
Buy-rated share 71% → 75% over ~3 months (+4pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Oct 2026 | $1.46 | $1.55 | +6.2% |
| Jul 2026 | $1.32 | $1.39 | +5.3% |
| Apr 2026 | $1.10 | $1.24 | +12.7% |
| Jan 2026 | $1.11 | $1.21 | +9.0% |
| Oct 2025 | $1.19 | $1.36 | +14.3% |
| Jul 2025 | $1.13 | $1.31 | +15.9% |
| Apr 2025 | $1.03 | $1.19 | +15.5% |
| Jan 2025 | $1.06 | $1.17 | +10.4% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 9.3%/yr (revenue basis).
Base free cash flow $301M (avg FY2023–FY2025; latest year $374M) · equity value $14.4B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 58 for Manhattan Associates indicates a moderately favorable outlook, driven by strong momentum and profitability scores of 69 and 61, respectively. The company's high return on equity of 97% and significant 12-month return of 38.7% contribute to its positive assessment. However, its value score is dragged down by a high P/E of 68.8 and P/B of 71.8, indicating a premium valuation. The short-term score of 63 diverges from the long-term score of 53, suggesting a recent surge in momentum.